Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:GPCR NYSE:RCUS NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.28+4.8%$5.47$1.85▼$7.18$825.77M1.182.91 million shs5.85 million shsGPCRStructure Therapeutics$45.61+0.2%$42.34$15.80▼$94.90$3.23B-1.35752,550 shs1.34 million shsRCUSArcus Biosciences$28.16+3.4%$24.40$7.91▼$28.72$3.42B0.851.28 million shs2.34 million shsRLAYRelay Therapeutics$17.44+0.9%$14.34$3.03▼$17.70$3.31B1.753.83 million shs5.39 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+4.76%+16.81%-0.56%-1.49%+121.85%GPCRStructure Therapeutics+0.22%+6.29%+16.38%-5.24%+106.38%RCUSArcus Biosciences+3.72%+19.34%+19.95%+31.37%+225.74%RLAYRelay Therapeutics+0.93%+15.88%+28.90%+81.67%+439.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.28+4.8%$5.47$1.85▼$7.18$825.77M1.182.91 million shs5.85 million shsGPCRStructure Therapeutics$45.61+0.2%$42.34$15.80▼$94.90$3.23B-1.35752,550 shs1.34 million shsRCUSArcus Biosciences$28.16+3.4%$24.40$7.91▼$28.72$3.42B0.851.28 million shs2.34 million shsRLAYRelay Therapeutics$17.44+0.9%$14.34$3.03▼$17.70$3.31B1.753.83 million shs5.39 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+4.76%+16.81%-0.56%-1.49%+121.85%GPCRStructure Therapeutics+0.22%+6.29%+16.38%-5.24%+106.38%RCUSArcus Biosciences+3.72%+19.34%+19.95%+31.37%+225.74%RLAYRelay Therapeutics+0.93%+15.88%+28.90%+81.67%+439.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.43Hold$16.00203.03% UpsideGPCRStructure Therapeutics 2.89Moderate Buy$110.55142.37% UpsideRCUSArcus Biosciences 2.58Moderate Buy$35.1024.64% UpsideRLAYRelay Therapeutics 3.00Buy$23.3033.60% UpsideCurrent Analyst Ratings BreakdownLatest ANNX, GPCR, RCUS, and RLAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026GPCRStructure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $70.006/4/2026RCUSArcus Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$46.005/26/2026RLAYRelay Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $26.005/26/2026RLAYRelay Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $28.005/20/2026RLAYRelay Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/20/2026RLAYRelay Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $27.005/20/2026RLAYRelay Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $21.005/19/2026RLAYRelay Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.005/19/2026RLAYRelay Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy5/19/2026RLAYRelay Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/19/2026RLAYRelay Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$23.00 ➝ $26.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$24.99 per shareN/ARCUSArcus Biosciences$247M14.34N/AN/A$5.84 per share4.82RLAYRelay Therapeutics$15.35M217.68N/AN/A$3.27 per share5.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)GPCRStructure Therapeutics-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)RCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)RLAYRelay Therapeutics-$276.48M-$1.57N/AN/AN/AN/A-43.94%-40.11%8/6/2026 (Estimated)Latest ANNX, GPCR, RCUS, and RLAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million5/5/2026Q1 2026RLAYRelay Therapeutics-$0.35-$0.41-$0.06-$0.41$5.58 million$3.00 million3/30/2026Q4 2025ANNXAnnexon-$0.32-$0.28+$0.04-$0.28$3.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35GPCRStructure TherapeuticsN/A26.1626.16RCUSArcus Biosciences0.194.044.04RLAYRelay TherapeuticsN/A22.1322.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AGPCRStructure Therapeutics91.78%RCUSArcus Biosciences92.89%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipANNXAnnexon10.31%GPCRStructure Therapeutics5.50%RCUSArcus Biosciences9.60%RLAYRelay Therapeutics5.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million146.95 millionOptionableGPCRStructure Therapeutics13671.07 million67.17 millionOptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableRLAYRelay Therapeutics330191.59 million181.93 millionOptionableANNX, GPCR, RCUS, and RLAY HeadlinesRecent News About These CompaniesRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Buy" by BrokeragesJune 20, 2026 | americanbankingnews.comRelay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is WhyJune 11, 2026 | insidermonkey.comRelay Therapeutics Expands Authorized Shares at 2026 MeetingJune 9, 2026 | tipranks.comRelay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 3, 2026 | seekingalpha.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneMay 27, 2026 | globenewswire.comRelay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular Anomalies - SlideshowMay 22, 2026 | seekingalpha.comRelay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data ReleaseMay 22, 2026 | finance.yahoo.comRelay Therapeutics prices $275M public offering of common stock at $12/shareMay 21, 2026 | msn.comRelay Therapeutics: Encouraging Data, Competitive Risks (Downgrade)May 21, 2026 | seekingalpha.comRLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisibMay 21, 2026 | msn.comRelay Therapeutics Prices Underwritten Public Offering of Common Stock Raising Approximately $275 MillionMay 20, 2026 | quiverquant.comQRelay Therapeutics Announces Pricing of Public Offering of Common StockMay 20, 2026 | globenewswire.comWhy Relay Therapeutics Stock Popped on WednesdayMay 20, 2026 | fool.comRelay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies - SlideshowMay 20, 2026 | seekingalpha.comRelay Therapeutics: Zovegalisib Is Becoming A Platform In DisguiseMay 20, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies TranscriptMay 19, 2026 | seekingalpha.comRelay Therapeutics Announces Proposed Public Offering of Common StockMay 19, 2026 | globenewswire.comRelay Therapeutics stock surges on vascular anomalies trial dataMay 19, 2026 | au.investing.comRelay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular ...May 19, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026Cheap Thrills: Why These 3 Entertainment Stocks Are SoaringBy Dan Schmidt | June 17, 2026ANNX, GPCR, RCUS, and RLAY Company DescriptionsAnnexon NASDAQ:ANNX$5.28 +0.24 (+4.76%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$5.32 +0.04 (+0.72%) As of 05:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Structure Therapeutics NASDAQ:GPCR$45.61 +0.10 (+0.22%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$45.60 -0.01 (-0.02%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Arcus Biosciences NYSE:RCUS$28.16 +0.93 (+3.42%) Closing price 06/23/2026 03:58 PM EasternExtended Trading$28.50 +0.34 (+1.21%) As of 05:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Relay Therapeutics NASDAQ:RLAY$17.44 +0.16 (+0.93%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$17.44 +0.00 (+0.03%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
